

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

VIFOR FRESENIUS MEDICAL CARE
RENAL PHARMA LTD., et al.,

Plaintiffs,

v.

TEVA PHARMACEUTICALS USA, INC.,

Defendant.

C.A. No. 18-390-MN

**STIPULATION REGARDING POST-TRIAL BRIEFING SCHEDULE,
PRODUCT LAUNCH, AND PRELIMINARY INJUNCTION MOTION PRACTICE**

Plaintiffs Vifor Fresenius Medical Care Renal Pharma Ltd. and Vifor Fresenius Medical Care Renal Pharma France S.A.S. (“Plaintiffs”) and Defendant Teva Pharmaceuticals USA, Inc. (“Defendant”), by and through their respective counsel and subject to the approval of the Court, hereby stipulate and agree to the following post-trial briefing schedule and page limits:

- Opening Briefs (maximum 30 pages regarding invalidity and 15 pages regarding infringement) and Findings of Fact due February 22, 2021;
- Responsive Briefs (maximum 30 pages regarding invalidity and 15 pages regarding infringement) and Responsive Findings of Facts due March 24, 2021;
- Reply Briefs due April 7, 2021 (maximum 10 pages regarding invalidity and 5 pages regarding infringement); and
- Hyperlinked briefs to be delivered to the Court on April 9, 2021.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Dated: February 9, 2021

Respectfully submitted,

By: /s/ Michael J. Farnan

Brian E. Farnan (Bar No. 4089)
Michael J. Farnan (Bar No. 5165)
FARNAN LLP
919 n. Market Str., 12th Floor
Wilmington, DE 19801
Tel: (302) 777-0300
Fax: (302) 777-0301
bfarnan@farnanlaw.com
mfarnan@farnanlaw.com

Attorneys for Plaintiffs

By: /s/ Karen E. Keller

John W. Shaw (No. 3362)
Karen E. Keller (No. 4489)
Nathan R. Hoeschen (No. 6232)
I.M. Pei Building
1105 North market Street, 12th Floor
Wilmington, DE 19801
(302) 298-0700
jshaw@shawkeller.com
kkeller@shawkeller.com
nhoeschen@shawkeller.com

*Attorneys for Defendant Teva
Pharmaceuticals USA, Inc.*

IT IS SO ORDERED this _____ day of February, 2021.

The Honorable Maryellen Noreika